At the European Cancer Congress (ECC) 2015, Laurence Albiges, MD, of Institut Gustave Roussy, Villejuif, France, discusses the results of clinical trials reported in patients with previously treated renal cell carcinoma: CheckMate 025, a phase 3 clinical trial of nivolumab versus everolimus; and METEOR, a phase 3 clinical trial of cabozantinib versus everolimus.
Changing the standard of care in previously treated metastatic renal cell carcinoma
9th December 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?